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Dr Todd Rosengart (Stony Brook, NY). I would like to congrat-
ulate the authors on a nice presentation. This is obviously an im-
portant clinical problem in the context of the prevalence of
diabetes in the western world and increasing heart failure as
a potential complication of this incidence.
My question goes to a little bit of the ‘‘cart–before-the-horse’’
dilemma. You created a model where you clearly demonstrate in-
sulin resistance and then subsequent heart failure, but I am not
quite sure that you have demonstrated a causal effect as opposed
to an intermediate step in your described pathophysiologic pro-
cess. So, I was wondering if you have thought about challenging
your system with antihyperglycemic rescue agents that can reverse
insulin resistance to show whether you can prevent heart failure in
your model system as a means of validating your hypothesis.
Dr Amorim. That is a very good point. Actually, there is a work
from Rong Tian inCirculation last year in which they used metfor-
min in infarcted rats and they found an improvement in survival,
although they only focused on AMPK activation. And, actually,
that is work in progress for us now; we are trying to see if metfor-
min or pioglitazone can improve cardiac function.
Dr Rosengart. Similarly, you mentioned that you began to look
at levels of Akt. You can similarly either downregulate Akt with
wortmannin or even potentially upregulate this system with gene
transfer of AKT as an alternative way of preventing your CHF
phenotype, so that may also help further prove that the insulinThe Journal of Thoracic and Carresistance is causal rather than maybe just an intermediate step.
Have you considered manipulating AKT in your models?
Dr Amorim. Well, the causal role is actually the focus of our
work now. But the point is that, even if cardiac insulin resistance
predisposes or is caused by contractile dysfunction, the focus is
that it is present in contractile dysfunction and it could be used
as a marker of heart failure.
Dr Rosengart. And, similarly, have you considered looking at
diabetic models as opposed to physiologic injury for your stimula-
tor of injury, in OB mice or the like?
Dr Amorim. Yes. But it is difficult to separate the vascular
commitment from the muscular.
Dr Rosengart. My last question is: In your abstract, you men-
tion that you measured dyspnea in the rats as a parameter. So, I just
needed to know how you assessed dyspnea in a rat; I was fasci-
nated by that.
Dr Amorim. Well, I can show some photos where you can see
that they are really blue and they are really short of breath and it is
easy to recognize, actually, if you see one.
Dr Pedro J. del Nido (Boston, Mass). One brief question. Mi-
tochondria seems to be a common theme here in a lot of the chronic
heart failure and also even in the ischemia-reperfusion models.
Insulin obviously is a very important growth factor and also for
mitochondrial biogenesis. Have you looked at the mitochondrial
component of your heart failure model?
Dr Amorim. Yes, we are working on that now.diovascular Surgery c Volume 140, Number 5 1167
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